Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Multicenter Study Evaluating the Safety and Efficacy of the Nicotine Replacement Therapy Chrono Quit Smoking Solution (CQSS2) System (21mg) Compared to the NicoDerm® CQ® Patch (21mg) for Smoking Cessation in Treatment Seeking Subjects

NCT03178422 is registered in ClinicalTrials.gov with Chrono Therapeutics, Inc. as lead sponsor.

NCT NCT03178422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03178422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Multicenter Study Evaluating the Safety and Efficacy of the Nicotine Replacement Therapy Chrono Quit Smoking Solution (CQSS2) System (21mg) Compared to the NicoDerm® CQ® Patch (21mg) for Smoking Cessation in Treatment Seeking Subjects
Lead sponsor
Chrono Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 7, 2017
Completion date
October 31, 2017
Enrollment
220 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

smoking cessation